148 related articles for article (PubMed ID: 8989068)
1. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
[TBL] [Abstract][Full Text] [Related]
2. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
[TBL] [Abstract][Full Text] [Related]
3. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
[TBL] [Abstract][Full Text] [Related]
4. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
[TBL] [Abstract][Full Text] [Related]
5. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group.
Portier H; May T; Proust A
J Antimicrob Chemother; 1996 May; 37 Suppl A():83-91. PubMed ID: 8737128
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on sparfloxacin (SPFX) in the treatment of mycoplasmal pneumonia and penetration of SPFX to the pneumonic lesion].
Hayashi Y; Ito G; Takeyama S
Kansenshogaku Zasshi; 1998 Jan; 72(1):54-9. PubMed ID: 9503785
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
Lipsky BA; Dorr MB; Magner DJ; Talbot GH
Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
[TBL] [Abstract][Full Text] [Related]
11. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.
Lode H; Garau J; Grassi C; Hosie J; Huchon G; Legakis N; Segev S; Wijnands G
Eur Respir J; 1995 Dec; 8(12):1999-2007. PubMed ID: 8666093
[TBL] [Abstract][Full Text] [Related]
12. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
Aubier M; Lode H; Gialdroni-Grassi G; Huchon G; Hosie J; Legakis N; Regamey C; Segev S; Vester R; Wijnands WJ; Tolstuchow N
J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
[TBL] [Abstract][Full Text] [Related]
15. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
16. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
[TBL] [Abstract][Full Text] [Related]
18. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
van Rensburg DJ; Perng RP; Mitha IH; Bester AJ; Kasumba J; Wu RG; Ho ML; Chang LW; Chung DT; Chang YT; King CH; Hsu MC
Antimicrob Agents Chemother; 2010 Oct; 54(10):4098-106. PubMed ID: 20660689
[TBL] [Abstract][Full Text] [Related]
20. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
Salvarezza CR; Mingrone H; Fachinelli H; Kijanczuk S
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():75-80. PubMed ID: 9579717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
